FDA approves private label ibuprofen PM
This article was originally published in The Tan Sheet
Executive Summary
FDA approves Perrigo's OTC ibuprofen and diphenhydramine citrate tablets, the Allegan, Mich.-based private-labeler says Dec. 29. Perrigo will ship the product in the first quarter of 2009. Estimated sales of the comparable Wyeth Consumer Healthcare product, Advil PM tablets, were $70 million in the 12 months ending Sept. 28 (1"The Tan Sheet" Nov. 3, 2008, In Brief)
You may also be interested in...
Perrigo readies ibuprofen/PM launch
The company says Oct. 29 it expects final clearance to launch a private-label version of Wyeth Consumer Healthcare's Advil PM tablets after Wyeth's exclusivity ends, Dec. 21, 2008. FDA granted tentative approval for Perrigo's abbreviated new drug application for the non-steroidal anti-inflammatory drug (ibuprofen 200 mg and diphenhydramine citrate 38 mg) indicated as a pain reliever and sleep-aid. According to Allegan, Mich.-based Perrigo, Advil PM U.S. sales totaled $70 million in the 12 months ending Sept. 28. Perrigo includes sales of an ibuprofen/diphenhydramine citrate product in the $275 million it expects to generate from more than 25 products launched between February 2007 and June 2009 (1"The Tan Sheet" Aug. 25, 2008, p. 11)
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.